VistaGen Therapeutics, Inc. (VTGN)
Automate Your Wheel Strategy on VTGN
With Tiblio's Option Bot, you can configure your own wheel strategy including VTGN - and automate your put writes, covered calls, and full wheel strategy. Just connect one of the supported brokerages: tastytrade, Schwab, TradeStation or Tradier and go.
Start Your Free Trial NowKey Metrics & Ratings
- symbol VTGN
- Rev/Share 0.0227
- Book/Share 2.6414
- PB 0.8973
- Debt/Equity 0.0211
- CurrentRatio 9.3484
- ROIC -0.6345
- MktCap 68403177.0
- FreeCF/Share -1.2784
- PFCF -1.7423
- PE -1.5387
- Debt/Assets 0.0186
- DivYield 0
- ROE -0.4812
- Rating B
- Score 3
- Recommendation Neutral
- P/E Score 1
- DCF Score 5
- P/B Score 4
- D/E Score 4
Recent Analyst Ratings
| Type | Ticker | Analyst Firm | Previous Rating | Current Rating | Previous Price Target | Current Price Target | Date |
|---|---|---|---|---|---|---|---|
| No ratings available. | |||||||
News
Vistagen on Track to Deliver Topline Data From Fasedienol PALISADE-3 Phase 3 Trial for Acute Treatment of Social Anxiety Disorder in the Fourth Quarter of This Year
Published: June 02, 2025 by: Business Wire
Sentiment: Neutral
SOUTH SAN FRANCISCO, Calif.--(BUSINESS WIRE)--Vistagen (Nasdaq: VTGN), a late clinical-stage biopharmaceutical company pioneering neuroscience with nose-to-brain neurocircuitry to develop and commercialize a new class of intranasal product candidates called pherines, today provides an update on the timeline for the ongoing clinical trials in its U.S. registration-directed PALISADE Phase 3 Program evaluating fasedienol for acute treatment of social anxiety disorder (SAD). The Company's PALISADE-.
Read More
Vistagen to Present at the 2025 American Society of Clinical Psychopharmacology Conference
Published: May 23, 2025 by: Business Wire
Sentiment: Neutral
SOUTH SAN FRANCISCO, Calif.--(BUSINESS WIRE)--Vistagen (Nasdaq: VTGN), a clinical-stage biopharmaceutical company pioneering neuroscience with nose-to-brain neurocircuitry to develop and commercialize a new class of intranasal product candidates called pherines, today announced it will present at the American Society of Clinical Psychopharmacology (ASCP) Conference in Scottsdale, Arizona from May 27-30, 2025. The Company's poster presentations will explore the age of onset of social anxiety dis.
Read More
Vistagen Therapeutics, Inc. (VTGN) Q3 2025 Earnings Call Transcript
Published: February 13, 2025 by: Seeking Alpha
Sentiment: Neutral
Vistagen Therapeutics, Inc. (NASDAQ:VTGN ) Q3 2025 Earnings Call Transcript February 13, 2025 5:00 PM ET Company Participants Mark McPartland - Senior Vice President of Investor Relations Shawn Singh - Chief Executive Officer and Director Cindy Anderson - Chief Financial Officer Josh Prince - Chief Operating Officer Conference Call Participants John Boyle - William Blair Operator Good day. Thank you for standing by.
Read More
VistaGen Therapeutics, Inc. (VTGN) Reports Q3 Loss, Misses Revenue Estimates
Published: February 13, 2025 by: Zacks Investment Research
Sentiment: Negative
VistaGen Therapeutics, Inc. (VTGN) came out with a quarterly loss of $0.46 per share versus the Zacks Consensus Estimate of a loss of $0.50. This compares to loss of $0.22 per share a year ago.
Read More
Vistagen Reports Fiscal Year 2025 Third Quarter Financial Results and Corporate Update
Published: February 13, 2025 by: Business Wire
Sentiment: Neutral
SOUTH SAN FRANCISCO, Calif.--(BUSINESS WIRE)--Vistagen (Nasdaq: VTGN), a clinical-stage biopharmaceutical company pioneering neuroscience with nose-to-brain neurocircuitry to develop and commercialize a new class of intranasal product candidates called pherines, today reported financial results for its fiscal year 2025 third quarter ended December 31, 2024, and provided a corporate update. “We had a very productive quarter, with both PALISADE-3 and PALISADE-4 advancing towards expected top-line.
Read More
About VistaGen Therapeutics, Inc. (VTGN)
- IPO Date 2011-06-21
- Website https://www.vistagen.com
- Industry Biotechnology
- CEO Mr. Shawn K. Singh J.D.
- Employees 48